Unicycive Therapeutics

(NASDAQ) UNCY

Current Price$6.94

Market Cap$198.38M

Since IPO (2021)-87%

5 YearN/A

1 Year-10%

1 Month-15%

Unicycive Therapeutics Financials at a Glance

Market Cap

$198.38M

Revenue (TTM)

$0.00

Net Income (TTM)

-$39.95M

EPS (TTM)

-$2.06

P/E Ratio

-3.61

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$6.94

Volume

1,201,319.005

Open

$7.41

Price

$6.94

Volume

1,201,319.005

Open

$7.41

Previous Close

$6.92

Daily Range

$6.86 - $7.41

52-Week Range

$3.71 - $11.00

Estimated Earnings Date

Aug 13, 2026

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$6.94

Volume

1,201,319.005

Open

$7.41

Previous Close

$6.92

Daily Range

$6.86 - $7.41

52-Week Range

$3.71 - $11.00

Estimated Earnings Date

Aug 13, 2026

UNCY News

Unicycive Posts 65% EPS Gain in Q2

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Unicycive Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Shalabh Gupta, MD

Website

www.unicycive.com

Headquarters

Los Altos, CA 94022, US

UNCY Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-163%

Return on Capital

-79%

Return on Assets

-62%

Earnings Yield

-27.70%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$198.38M

Shares Outstanding

26.70M

Volume

1.20M

Avg. Volume

576.50K

Financials (TTM)

Gross Profit

-$572.00K

Operating Income

-$29.52M

EBITDA

-$25.91M

Operating Cash Flow

-$31.32M

Capital Expenditure

-$24.00K

Free Cash Flow

-$31.34M

Cash & ST Invst.

$41.27M

Total Debt

$117.00K

Unicycive Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$211.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$198.38M

N/A

Market Cap/Employee

$9.02M

N/A

Employees

N/A

Net Income

-$12.82M

-2349.6%

EBITDA

-$8.23M

-1242.5%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$53.77M

+181.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$217.00K

N/A

Short Term Debt

$598.00K

-13.8%

Return on Assets

-62.03%

N/A

Return on Invested Capital

-79.02%

N/A

Free Cash Flow

-$6.25M

+29.9%

Operating Cash Flow

-$6.24M

+29.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IMUXImmunic, Inc.

IMUXImmunic, Inc.$12.77-11.50%

RPTXRepare Therapeutics Inc.

RPTXRepare Therapeutics Inc.$2.65+0.00%

CAMPCAMP4 Therapeutics Corporation

CAMPCAMP4 Therapeutics Corporation$4.11-4.42%

HYFTMindWalk Holdings Corp.

HYFTMindWalk Holdings Corp.$1.68-9.19%

BMEABiomea Fusion, Inc.

BMEABiomea Fusion, Inc.$1.27-7.30%

PMVPPMV Pharmaceuticals, Inc.

PMVPPMV Pharmaceuticals, Inc.$1.12-5.88%

CBUSCibus, Inc.

CBUSCibus, Inc.$1.29-7.86%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$73.05-0.14%

KEELKeel Infrastructure

KEELKeel Infrastructure$5.13-0.13%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$43.19+0.14%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$34.14-0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.50+0.02%

QQQInvesco QQQ Trust

QQQInvesco QQQ Trust$705.06-0.05%

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF$11.87-0.11%

Questions About UNCY

What is the current price of Unicycive Therapeutics?

Unicycive Therapeutics is trading at $6.92 per share.

What is the 52-week range for Unicycive Therapeutics?

Over the past 52 weeks, Unicycive Therapeutics has traded between $3.71 and $11.00.

How much debt does Unicycive Therapeutics have?

As of the most recent reporting period, Unicycive Therapeutics reported total debt of $941.00K.

How much cash does Unicycive Therapeutics have on hand?

Unicycive Therapeutics reported $37.37M in cash and cash equivalents in its most recent financial results.

What is Unicycive Therapeutics’s dividend yield?

Unicycive Therapeutics does not currently have a dividend yield.

Unicycive Therapeutics

Unicycive Therapeutics Financials at a Glance

UNCY News

Unicycive Posts 65% EPS Gain in Q2

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Unicycive Therapeutics

UNCY Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Unicycive Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About UNCY

What is the current price of Unicycive Therapeutics?

What is the 52-week range for Unicycive Therapeutics?

How much debt does Unicycive Therapeutics have?

How much cash does Unicycive Therapeutics have on hand?

What is Unicycive Therapeutics’s dividend yield?

Premium Investing Services